The use of pharmacoeconomics in formulary development: can this improve the way deep vein thrombosis is treated?
A study of the Prescription Solutions database revealed that in 2000 the average pharmacy plus medical costs per patient with deep vein thrombosis (DVT) were $60,019. The total charges for this group of patients in this organization were $389 million. The cost of treating these patients is relatively high, and there may be opportunities to significantly improve the quality and overall cost effectiveness of their care. One example of how this might be accomplished is by developing a pharmacy-based DVT predictive model that could be used proactively to identify patients who may be at risk for DVT and who might benefit from early intervention with low-molecular-weight heparin therapy prophylaxis.